Literature DB >> 31009013

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens.

Amy V Paschall1, Dustin R Middleton1, Fikri Y Avci2.   

Abstract

A key aspect of the immune response to bacterial colonization of the host is phagocytosis. An opsonophagocytic killing assay (OPKA) is an experimental procedure in which phagocytic cells are co-cultured with bacterial units. The immune cells will phagocytose and kill the bacterial cultures in a complement-dependent manner. The efficiency of the immune-mediated cell killing is dependent on a number of factors and can be used to determine how different bacterial cultures compare with regard to resistance to cell death. In this way, the efficacy of potential immune-based therapeutics can be assessed against specific bacterial strains and/or serotypes. In this protocol, we describe a simplified OPKA that utilizes basic culture conditions and cell counting to determine bacterial cell viability after co-culture with treatment conditions and HL-60 immune cells. This method has been successfully utilized with a number of different pneumococcal serotypes, capsular and acapsular strains, and other bacterial species. The advantages of this OPKA protocol are its simplicity, versatility (as this assay is not limited to antibody treatments as opsonins), and minimization of time and reagents to assess basic experimental groups.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31009013      PMCID: PMC7201466          DOI: 10.3791/59400

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  20 in total

Review 1.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

2.  Opsonophagocytic assay.

Authors:  Markryan Dwyer; Mihaela Gadjeva
Journal:  Methods Mol Biol       Date:  2014

3.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

4.  Potential use of intravenous immune globulin for group B streptococcal infection.

Authors:  C J Baker; F J Noya
Journal:  Rev Infect Dis       Date:  1990 May-Jun

5.  Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model.

Authors:  Nikkol Melnick; Gowrisankar Rajam; George M Carlone; Jacquelyn S Sampson; Edwin W Ades
Journal:  Clin Vaccine Immunol       Date:  2009-04-22

6.  Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.

Authors:  S J Collins; F W Ruscetti; R E Gallagher; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

7.  Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.

Authors:  Haijun Tian; Sarah Weber; Peter Thorkildson; Thomas R Kozel; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

8.  Identification and characterization of the Streptococcus pneumoniae type 3 capsule-specific glycoside hydrolase of Paenibacillus species 32352.

Authors:  Dustin R Middleton; Xing Zhang; Paeton L Wantuch; Ahmet Ozdilek; Xinyue Liu; Rachel LoPilato; Nikhil Gangasani; Robert Bridger; Lance Wells; Robert J Linhardt; Fikri Y Avci
Journal:  Glycobiology       Date:  2018-02-01       Impact factor: 4.313

9.  Enzymatic Hydrolysis of Pneumococcal Capsular Polysaccharide Renders the Bacterium Vulnerable to Host Defense.

Authors:  Dustin R Middleton; Amy V Paschall; Jeremy A Duke; Fikri Y Avci
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

10.  Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus.

Authors:  Jasdeep S Nanra; Sandra M Buitrago; Shomari Crawford; Jennifer Ng; Pamela S Fink; Julio Hawkins; Ingrid L Scully; Lisa K McNeil; José Miguel Aste-Amézaga; David Cooper; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

View more
  6 in total

Review 1.  Studying Neutrophil Function in vitro: Cell Models and Environmental Factors.

Authors:  Marfa Blanter; Mieke Gouwy; Sofie Struyf
Journal:  J Inflamm Res       Date:  2021-01-20

2.  Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection.

Authors:  Jiachen Huang; Aaron D Gingerich; Fredejah Royer; Amy V Paschall; Alma Pena-Briseno; Fikri Y Avci; Jarrod J Mousa
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

3.  Development and Immunogenicity of a Prototype Multivalent Group B Streptococcus Bioconjugate Vaccine.

Authors:  Jeremy A Duke; Amy V Paschall; Lloyd S Robinson; Cory J Knoot; Evgeny Vinogradov; Nichollas E Scott; Mario F Feldman; Fikri Y Avci; Christian M Harding
Journal:  ACS Infect Dis       Date:  2021-10-11       Impact factor: 5.084

Review 4.  Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.

Authors:  David Goldblatt; Galit Alter; Shane Crotty; Stanley A Plotkin
Journal:  Immunol Rev       Date:  2022-06-05       Impact factor: 10.983

5.  Evaluation of PLGA nanoparticles containing outer membrane proteins of Acinetobacter baumannii bacterium in stimulating the immune system in mice.

Authors:  Afshin Gholizadeh; Reza Shapoury; Parviz Pakzad; Mehdi Mahdavi; Hossein Danafar
Journal:  Res Pharm Sci       Date:  2022-07-14

6.  A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.

Authors:  Ahmet Ozdilek; Jiachen Huang; Rachelle Babb; Amy V Paschall; Dustin R Middleton; Jeremy A Duke; Liise-Anne Pirofski; Jarrod J Mousa; Fikri Y Avci
Journal:  mBio       Date:  2021-06-01       Impact factor: 7.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.